Brian Kim, EADV 2021: Difelikefalin for Pruritus in Atopic Dermatitis
It was a pleasure to meet up with Dr Brian Kim (Washington University School of Medicine, St. Louis, MO, USA) to talk about the use of difelikefalin in treating pruritus associated with atopic dermatitis (AD).
His presentation entitled ‘Oral Difelikefalin Reduces Pruritus in Atopic Dermatitis’ was given at the EADV 30th Congress, 29 Sep – 2 Oct 2021.
- Could you tell us a little about oral difelikefalin and the rationale for its use in patients with AD and pruritus? (0:17)
- What was the design of the KARE Phase II study and how were patients stratified? (1:19)
- What were the efficacy endpoints and how well were they achieved? (2:32)
- On the basis of these findings, where do you see difelikefalin sitting in the treatment paradigm for pruritus? (2:55)
Disclosures: Dr Brian Kim has acted as a consultant for AbbVie, AstraZeneca, Cara Therapeutics, Galderma, GlaxoSmithKline, LEO Pharma, Eli Lilly, Pfizer, Regeneron, Sanofi and Trevi Therapeutics and undertaken contracted research for Cara Therapeutics and LEO Pharma.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EADV’s 30th Congress, 29 Sep – 2 Oct 2021.
Share this Video
Related Videos In Atopic Dermatitis
Amy Paller, Dermatology Meeting News 2023: The efficacy of dupilumab in children with atopic dermatitis
Dupilumab is a monoclonal antibody approved for use in patients with atopic dermatitis that is not well controlled with topical treatments, or who are unable to use topical treatments. It was a pleasure to talk with Prof Amy Paller (Northwestern University Feinberg School of Medicine; Lurie Children’s Hospital of Chicago, Chicago, IL, USA) about the […]
Amy Paller, Dermatology Meeting News 2023: Current treatment paradigm for atopic dermatitis in children
Atopic dermatitis is a chronic skin disorder causing inflammation, redness and irritation of the skin, and usually begins in childhood. touchIMMUNOLOGY caught up with Prof Amy Paller (Northwestern University Feinberg School of Medicine; Lurie Children’s Hospital of Chicago, Chicago, IL, USA), to discuss the current treatment paradigm for atopic dermatitis in children, and factors that […]
Melinda Gooderham, Dermatology Meeting News 2023: Abrocitinib efficacy in atopic dermatitis by baseline disease severity – findings from an interim analysis of JADE EXTEND
JADE-EXTEND (NCT03422822) is a phase 3 long-term extension study investigating the efficacy and safety of abrocitinib in atopic dermatitis. In this touchIMMUNOLOGY interview, we caught up with Dr. Melinda Gooderham (SKiN Centre for Dermatology, Ontario, Canada) around her interim analysis of JADE-EXTEND, looking at efficacy by baseline disease severity. The abstract ‘Influence of Baseline Disease […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!